MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
MediciNova (NASDAQ: MNOV) has announced its participation in the upcoming Inaugural DBC Conference organized by D. Boral Capital on May 14, 2025 at the Plaza Hotel, New York City.
The company's leadership team, including CEO Dr. Yuichi Iwaki and CBO Dr. David H. Crean, will engage in investor meetings during the conference. They will present MediciNova's leading programs focused on neurologic and metabologic disorders.
The conference will facilitate interactions between public and private executives and various investor groups, including institutional investors, high-net worth individuals, and corporate clients, with a particular focus on Healthcare & Life Sciences sectors.
MediciNova (NASDAQ: MNOV) ha annunciato la sua partecipazione alla prima edizione della Conferenza DBC organizzata da D. Boral Capital il 14 maggio 2025 presso il Plaza Hotel di New York City.
Il team dirigenziale dell'azienda, incluso il CEO Dr. Yuichi Iwaki e il CBO Dr. David H. Crean, parteciperà a incontri con investitori durante la conferenza. Presenteranno i programmi di punta di MediciNova, focalizzati su disturbi neurologici e metabolici.
La conferenza faciliterà l’interazione tra dirigenti di aziende pubbliche e private e vari gruppi di investitori, inclusi investitori istituzionali, persone con un alto patrimonio e clienti aziendali, con particolare attenzione ai settori Healthcare e Life Sciences.
MediciNova (NASDAQ: MNOV) ha anunciado su participación en la Conferencia Inaugural DBC organizada por D. Boral Capital el 14 de mayo de 2025 en el Plaza Hotel de la ciudad de Nueva York.
El equipo directivo de la empresa, incluyendo al CEO Dr. Yuichi Iwaki y al CBO Dr. David H. Crean, se reunirá con inversores durante la conferencia. Presentarán los programas principales de MediciNova enfocados en trastornos neurológicos y metabólicos.
La conferencia facilitará las interacciones entre ejecutivos de empresas públicas y privadas y diversos grupos de inversores, incluyendo inversores institucionales, individuos con alto patrimonio y clientes corporativos, con un enfoque especial en los sectores de Salud y Ciencias de la Vida.
MediciNova (NASDAQ: MNOV)는 2025년 5월 14일 뉴욕 플라자 호텔에서 D. Boral Capital이 주최하는 첫 번째 DBC 컨퍼런스에 참여한다고 발표했습니다.
회사의 리더십 팀인 CEO Dr. Yuichi Iwaki와 CBO Dr. David H. Crean이 컨퍼런스 기간 동안 투자자 미팅에 참여할 예정입니다. 이들은 신경 및 대사 질환에 중점을 둔 MediciNova의 주요 프로그램을 발표할 것입니다.
이번 컨퍼런스는 공공 및 민간 기업 임원들과 기관 투자자, 고액 자산가, 법인 고객 등 다양한 투자자 그룹 간의 교류를 촉진하며, 특히 헬스케어 및 생명과학 분야에 중점을 둘 예정입니다.
MediciNova (NASDAQ : MNOV) a annoncé sa participation à la première conférence DBC organisée par D. Boral Capital le 14 mai 2025 au Plaza Hotel de New York.
L’équipe dirigeante de l’entreprise, comprenant le PDG Dr Yuichi Iwaki et le CBO Dr David H. Crean, participera à des réunions avec des investisseurs durant la conférence. Ils présenteront les programmes phares de MediciNova axés sur les troubles neurologiques et métaboliques.
La conférence facilitera les échanges entre dirigeants d’entreprises publiques et privées et divers groupes d’investisseurs, incluant des investisseurs institutionnels, des particuliers fortunés et des clients d’entreprise, avec un accent particulier sur les secteurs de la santé et des sciences de la vie.
MediciNova (NASDAQ: MNOV) hat seine Teilnahme an der bevorstehenden ersten DBC-Konferenz angekündigt, die von D. Boral Capital am 14. Mai 2025 im Plaza Hotel in New York City veranstaltet wird.
Das Führungsteam des Unternehmens, darunter CEO Dr. Yuichi Iwaki und CBO Dr. David H. Crean, wird während der Konferenz Investorengespräche führen. Sie werden MediciNovas führende Programme vorstellen, die sich auf neurologische und metabolische Erkrankungen konzentrieren.
Die Konferenz fördert den Austausch zwischen Führungskräften öffentlicher und privater Unternehmen sowie verschiedenen Investorengruppen, darunter institutionelle Investoren, vermögende Privatpersonen und Firmenkunden, mit besonderem Fokus auf die Bereiche Healthcare & Life Sciences.
- None.
- None.
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital’s, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private executives with institutional investors, high-net worth individuals, and corporate clients from various sectors including Healthcare & Life Sciences. Drs. Iwaki and Crean will be discussing MediciNova’s leading programs in neurologic and metabologic disorders. For more information about participation in the DBC Conference, visit https://dboralcapital.com/conference.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. The company’s current strategy is to focus their development activities on MN-166 (ibudilast) for neurological and other disorders such as amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD) and hypertriglycedemia. The company intends to advance their pipeline through a combination of investigator-sponsored clinical trials, trials funded through government grants or other grants, trials funded on their own, or through strategic alliances to help support further clinical development of their lead programs.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ
When and where is MediciNova (MNOV) presenting at the DBC Conference?
What will MediciNova (MNOV) discuss at the D. Boral Capital Conference?
Which MediciNova executives will attend the DBC Conference 2025?
What type of investors will attend the D. Boral Capital Conference where MNOV is presenting?
